|
VAPB expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62414526272414E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.11022302462516E-16 |
| Normal-vs-Stage2 |
1.61319999999465E-05 |
| Normal-vs-Stage3 |
1.62447832963153E-12 |
| Normal-vs-Stage4 |
<1E-12 |
| Stage1-vs-Stage2 |
1.721540E-02 |
| Stage1-vs-Stage3 |
9.290200E-02 |
| Stage1-vs-Stage4 |
1.63102999999332E-05 |
| Stage2-vs-Stage3 |
2.459700E-03 |
| Stage2-vs-Stage4 |
4.33490000000258E-05 |
| Stage3-vs-Stage4 |
1.854400E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
5.74470027103757E-10 |
| Normal-vs-Asian |
1.11022302462516E-16 |
| Caucasian-vs-AfricanAmerican |
9.107000E-01 |
| Caucasian-vs-Asian |
3.922000E-01 |
| AfricanAmerican-vs-Asian |
6.867800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.33226762955019E-15 |
| Normal-vs-Female |
4.44089209850063E-16 |
| Male-vs-Female |
7.885200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62458935193399E-12 |
| Normal-vs-Age(41-60Yrs) |
1.11022302462516E-16 |
| Normal-vs-Age(61-80Yrs) |
1.62658775337832E-12 |
| Normal-vs-Age(81-100Yrs) |
3.84740000000106E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.271600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.780200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.465600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.559200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.778800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.842600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.181300E-04 |
| Classical-VS-Follicular |
3.353400E-04 |
| Classical-VS-Other |
7.009000E-01 |
| Classical-VS-Normal |
4.44089209850063E-16 |
| Tall-VS-Follicular |
5.43070000080803E-08 |
| Tall-VS-Other |
3.341000E-01 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
5.490200E-01 |
| Follicular-VS-Normal |
1.19239995655107E-09 |
| Other-VS-Normal |
1.497330E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.11022302462516E-16 |
| Normal-vs-N1 |
1.62436730732907E-12 |
| N0-vs-N1 |
8.0941000000001E-05 |
|
|
